Induction androgen deprivation plus prostatectomy for stage T3 disease: Failure to achieve prostate-specific antigen-based freedom from disease status in a phase II trial

Urology

Volumn 47, Issue 6, 1996, Pages 870-877

  Gomella, Leonard G ^a,b   Liberman, Stuart N ^a   Mulholland, S Grant ^a   Petersen, Robert O ^a   Hyslop, Theresa ^a   Corn, Benjamin W ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUTAMIDE; LEUPRORELIN;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; HUMAN; MALE; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; TREATMENT OUTCOME;

EID: 0029903211     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(96)00041-6     Document Type: Article

References (44)

1. Beahrs OH, Henson DE, Hutter RVP, and Kennedy BJ: Manual for Staging of Cancer, 4th ed. Philadelphia, JB Lippincott, 1992, pp 487-512.
2. Corn BW, and Hanks GE: Management of stage T3 adenocarcinoma of the prostate, in Raghavan D, Scher H, Leiber SA, and Lange P (Eds): Principles and Practices of Genitourinary Oncology. Philadelphia, JB Lippincott, 1996.
3. Boxer RJ, Kaufman JJ, and Goodwin WE: Radical prostatectomy for carcinoma of the prostate (1951-1976): a review of 329 cases. J Urol 117: 208-213, 1977.
4. Tomlinson RL, Currie DP, and Boyce WH: Radical prostatectomy: palliation for stage C carcinoma of the prostate. J Urol 117: 85-87, 1977.
5. Lee WR, Hanks GE, Schultheiss TE, Corn BW, and Hunt MA: Localized prostate cancer treated by external beam radiotherapy alone: serum PSA driven outcome analysis. J Clin Oncol 13: 464-469, 1995.
6. Russell KJ, Laramore GE, Krall JM, Thomas FJ, Maor MH, and Hendrickson FR: Eight years experience with neutron radiotherapy in the treatment of stages C and D prostate cancer: updated results of the RTOG 77-04 randomized clinical trial. Prostate 11: 183-193, 1987.
7. Shipley WU, Verhey LJ, Munzenrider JE, Suit HD, Urie MM, McManus PL, Young RH, Shipley JW, Zietman AL, Biggs PJ, et al: Advanced prostate cancer: the results of a randomized comparative trial of high dose irradiation boosting with conformai protons compared with conventional dose irradiation using photons alone. Int J Radiat Oncol Biol Phys 32: 3-12, 1995.
8. Flamm J, Fischer M, Holtl W, Pfluger H, and Tomschi W: Complete androgen deprivation prior to radical prostatectomy in patients with stage T3 cancer of the prostate. Eur Urol 19: 192-195, 1991.
9. Kennedy TJ, Sonneland AM, Marlett MM, and Troup RH: Luteinizing hormone-releasing hormone downstaging of clinical stage C prostate cancer. J Urol 147: 891-893, 1992.
10. Pilepich MV, Krall J, Al-Sarraf M, Roach M, Doggett RL, Sause W, Lawton CA, Abrams RA, Rotman M, Rubin P, et al: A phase III trial of androgen suppression before and during radiation therapy for locally advanced prostatic carcinoma: preliminary report of RTOG protocol 8610. Proc Annu Meet Am Soc Clin Oncol 12: A703, 1993.
11. Pilepich MV, Buzydlowski JW, John MJ, Rubin P, McGowan DG, and Marcial VA: Phase II trial of hormonal cytoreduction with megestrol and diethylstilbestrol in conjunction with radiotherapy for carcinoma of the prostate: outcome results of RTOG 83-07. Int J Radiat Oncol Biol Phys 32: 175-180, 1995.
12. Zagars GK, Johnson DE, von Eschenbach AC, and Hussey DH: Adjuvant estrogen following radiation therapy for stage C adenocarcinoma of the prostate: long term results of a prospective randomized study. Int J Radiat Oncol Biol Phys 14: 1085-1091, 1988.
13. Zincke H: Bilateral pelvic lymphadenectomy and radical retropubic prostatectomy for stage C and D1 adenocarcinoma of the prostate: possible beneficial effect of adjuvant treatment. Natl Cancer Inst Monogr 7: 109-115, 1988.
14. Van Poppel H, De Ridder D, Elgamal AA, Van de Voorde W, Werbrouck P, Ackaert K, Oyen R, Pittomvils G, and Baert L: Neoadjuvant hormonal therapy before radical prostatectomy decreases the number of positive surgical margins in stage T2 prostate cancer: interim results of a prospective randomized trial. The Belgium Uro-Oncological Group. J Urol 154 (2 pt 1): 429-434, 1995.
15. Soloway MS, Sharifi R, Wajsman Z, McLeod D, Wood DPJr, and Puras-Baez A: Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. J Urol 154: 424-428, 1995.
16. Fair WR, Aprikian A, Sogani P, Reuter V, and Whitmore WF Jr: The role of neoadjuvant hormonal manipulation in localized prostatic cancer. Cancer 71: 1031-1038, 1993.
17. Labrie F, Cusan L, Gomez J, Diamond P, Suburu R, Martin L, Tetu B, Fradet Y, and Candas B: Down staging of early stage prostate cancer before radical prostatectomy: the first randomized trial of neoadjuvant combination therapy with flutamide and a luteinizing hormone-releasing hormone agonist. Urology 44: 29-36, 1994.
18. Oesterling JE, Chan DW, Epstein JI, Kimball AW Jr, Bruzek DJ, Rock RC, Brendler CB, and Walsh PC: Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. J Urol 139: 766-772, 1988.
19. Pummer K, Crawford ED, Daneshgari F, Andros EA, Pfister S, and Miller GJ: Hormonal pretreatment does not affeet the final pathological stage in locally advanced prostate cancer. Urology 44(6A): 38-42, 1994.
20. Andros EA, Danesghari F, and Crawford ED: Neoadjuvant hormonal therapy in stage C adenocarcinoma of the prostate. Clin Invest Med 16: 510-515, 1993.
21. Narayan P, Lowe BA, Carroll PR, and Thompson IM: Neoadjuvant hormonal therapy and radical prostatectomy for clinical stage C carcinoma of the prostate. Br J Urol 73: 544-548, 1994.
22. Walsh PC, Lepor H, and Eggleston JC: Radical prostatectomy with preservation of sexual function: anatomical and pathological considerations. Prostate 4: 473-485, 1983.
23. Kaplan EL, and Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-459, 1958.
24. Cox DR: Analysis of Binary Data. London, Chapman & Hall, 1980, pp 55-73.
25. Cancer Fact and Figures-1995. American Cancer Society, Atlanta, 1995.
26. Hanks GE: External beam radiation treatment for prostate cancer: still the gold standard. Oncology 6: 79-94, 1992.
27. Bagshaw MA: Potential for radiotherapy alone in prostatic cancer. Cancer 55: 2079-2085, 1985.
28. Zagars GK, von Eschenbach AC, Johnson DE, and Oswald MJ: Stage C adenocarcinoma of the prostate: an analysis of 551 patients treated with external beam radiation. Cancer 60: 1489-1499, 1987.
29. Lu-Yao GL, McLerran D, Wasson J, and Wennberg JE: An assessment of radical prostatectomy. Time trends, geographic variation, and outcomes. The Prostate Patient Outcomes Research Team. JAMA 269: 2633-2636, 1993.
30. Donahue RE, Mani JH, Whitesel JA, Mohr S, Scanavino D, Augspurger RR, Biber RJ, Fauver HE, Wettlaufer JN, and Pfister RR: Pelvic lymph node dissection. Guide to patient management in clinically locally confined adenocarcinoma of the prostate. Urology 20: 559-565, 1982.
31. Lerner SE, Blute ML, and Zincke H: Extended experience with radical prostatectomy for clinical stage T3 prostate cancer: outcome and contemporary morbidity. J Urol 154: 1447-1452, 1995.
32. Vallett BS: Radical perineal prostatectomy subsequent to bilateral orchiectomy. Delaware State Med J 16: 19, 1944.
33. Zagars GK, Geara FB, Pollack A, and von Eschenbach AC: The T classification of clinically localized prostate cancer: an appraisal based on disease outcome after radiation therapy. Cancer 73: 1904-1912, 1994.
34. Corn BW, Hanks GE, Lee WR, and Schultheiss TE: Does the current subclassification of stage T3 adenocarcinoma of the prostate have clinical relevance? Urology 45: 484-489, 1995.
35. Zietman AL, Coen JJ, Shipley WU, and Efird JT: Radical radiation therapy in the management of prostatic adenocarcinoma: the initial prostate specific antigen value as a predictor of treatment outcome. J Urol 151: 640-645, 1994.
36. Liberman S, Mulholland SG, Outwater E, and Gomella LG: MR imaging of the prostate with endorectal surface coil: correlation with neoadjuvant hormonal down staging. J Urol 153: 238A, 1995.
37. Colombel M, Olsson CA, Ng PY, and Buttyan R: Hormone-regulated apoptosis results from re-entry of differentiated prostate cells onto a defective cell cycle. Cancer Res 52: 4313-4319, 1992.
38. Pollack A, Zagars GK, and Kopplin S. Radiotherapy and androgen ablation for clinically localized high-risk prostate cancer. Int J Radiat Oncol Biol Phys 32: 13-20, 1995.
39. Pilepich MV, Krall JM, al-Sarraf M, John MJ, Doggett RL, Sause WT, Lawton CA, Abrams RA, Rotman M, Rubin P, et al: Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group. Urology 45: 616-623, 1995.
40. Moreno JG, Croce CM, Fischer R, Monne M, Vihko P, Mulholland SG, and Gomella LG: Detection of hematogenous micrometastasis in patients with prostate cancer. Cancer Res 52: 6110-6112, 1992.
41. Fair WR, Israeli RS, Wang Y, Nawabe MD, Edwards ET, and Heston DW: Neoadjuvant androgen-deprivation therapy (ADT) prior to radical prostatectomy results in significantly decreased incidence of residual micrometastatic disease as detected by nested RT-PCR with PSM primers. J Urol 153: 391A, 1995.
42. Hudes GR, Greenberg R, Krigel RL, Fox S, Scher R, Litwin S, Watts P, Speicher L, Tew K, and Comis R: Phase II study of estramustine and vinblastine, two microtubule inhibitors in hormone refractory prostate cancer. J Clin Oncol 10: 1754-1761, 1992.
43. Choy H, Rodriguez FF, Koester S, Hilsenbeck S, and Von Hoff DD: Investigation of Taxol as a potential radiation sensitizer. Cancer 71: 3774-3778, 1993.
44. Gleave ME, Goldenberg SL, Jones EL, Bruchovsky N, and Sullivan LD: Maximal biochemical and pathological downstaging requires 8 months of neoadjuvant hormonal therapy prior to radical prostatectomy. J Urol 153: 392A, 1995.